Product
Tarloxotinib
1 clinical trial
9 indications
Indication
NSCLCIndication
Stage IVIndication
Non-Small Cell Lung Cancer Stage IIIBIndication
Stage IIICIndication
RecurrentIndication
EGFR Exon 20 Insertion MutationIndication
HER2-activating MutationIndication
ERBB FusionIndication
NRG1 Fusion